Recurrent Erythema Multiforme Not Responding to Antiviral Prophylaxis

Clinical Scenario

This protocol covers recurrent erythema multiforme — whether the recurrences are HSV-associated or occur without an identifiable trigger (idiopathic). In both presentations, antiviral prophylaxis is the established first-line management.

When First-Line Treatment Has Not Worked

Patients who have received continuous oral antiviral prophylaxis — with acyclovir, valacyclovir, or famciclovir — and have not achieved the expected goals of reduced recurrence frequency and induction of remission require a revised approach.

This protocol defines the structured next step for those non-responsive cases.

Next-Step Approach

When recurrent erythema multiforme is refractory to initial antiviral prophylaxis, an adjustment to the antiviral strategy is indicated — the full evidence-based regimen is available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/medicina57090921

In both HSV-associated EM and idiopathic EM, the first-line treatment is antiviral prophylaxis.

Patients with recurrent EM that are unresponsive to antiviral therapy can try other antiviral drugs or double the dosage of the current drug.

For non-responsive EM, another antiviral medication may be substituted, or the dose of the current antiviral doubled.

View source ↗